AMENDMENT

IN THE CLAIMS:

Please amend the claims as follows:

Claims 1-13 (Canceled)

14. (Currently amended) A method for expressing a gene in at least one eye cell, comprising:

a) administering by subretinal injection or intravitreous injection to at least one eye cell a defective recombinant adenovirus comprising an inserted gene, wherein the inserted gene comprises at least one sequence permitting its expression in the eye cell;

b) infecting the at least one eye cell with the defective recombinant adenovirus; and

c) expressing the gene.

15. (Previously Presented) The method of claim 14, wherein the defective recombinant adenovirus is a type AD 2 adenovirus.

16. (Previously Presented) The method of claim 14, wherein the defective recombinant adenovirus is a type AD 5 adenovirus.

17. (Previously Presented) The method of claim 14, wherein the gene encodes a protein.

18. (Previously Presented) The method of claim 17, wherein the protein is growth factor, cytokine, neurotrophin, regulatory factor, enzyme, interferon, or tumor necrosis factor.

19. (Currently Amended) The method of claim 18, wherein the protein is ornithine aminotransferase, rhodopsin, RDS (retinal degradation slow) peripherin, tyrosinase, mitochondrial NDI (NADH-dehydrogenase subunit 1), the β subunit of cGMP phosphodiesterase, rab geranyl transferase, basic fibroblast growth factor, or interleukin-8.

20. (Previously Presented) The method of claim 14, wherein the gene encodes an antisense RNA molecule.

21. (Previously Presented) The method of claim 14, wherein the defective recombinant adenovirus has a genome lacking at least one region needed to replicate in the eye cell.

22. (Canceled)

23. (Currently Amended) The method of claim 14 ~~22~~, wherein the subretinal injection is carried out in the vitreous, anterior chamber, or the retrobulbar space.

24. (Previously Presented) The method of claim 14, there the at least one eye cell is a corneal endothelium cell, photoreceptor cell, bipolar cell, ganglion cell, or oculomotor cell.

25. (Currently Amended) The method of claim 14, wherein the sequence permitting expression of the gene is a Rous Sarcoma Virus promoter, E1A promoter, or MLP (major late promoter) promoter.

26. (Previously Presented) The method according to claim 21, wherein the at least one region needed to replicate in the eye cell is an E1A or E1B region.